Open AccessJournal Article
Statistical methods in cancer research. Volume I - The analysis of case-control studies.
N. E. Breslow,N. E. Day +1 more
Reads0
Chats0
About:
This article is published in IARC scientific publications.The article was published on 1980-01-01 and is currently open access. It has received 4614 citations till now.read more
Citations
More filters
Journal ArticleDOI
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study
Salim Yusuf,Steven Hawken,Stephanie Ôunpuu,Tony Dans,Alvaro Avezum,Fernando Lanas,Matthew J. McQueen,Andrzej Budaj,Prem Pais,John Varigos,Liu Lisheng +10 more
TL;DR: Abnormal lipids, smoking, hypertension, diabetes, abdominal obesity, psychosocial factors, consumption of fruits, vegetables, and alcohol, and regular physical activity account for most of the risk of myocardial infarction worldwide in both sexes and at all ages in all regions.
Journal ArticleDOI
Reconsidering Baron and Kenny: Myths and Truths about Mediation Analysis
TL;DR: Baron and Kenny's procedure for determining if an independent variable affects a dependent variable through some mediator is so well known that it is used by authors and requested by reviewers almost reflexively.
Journal ArticleDOI
Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer
Nubia Muñoz,F. Xavier Bosch,Silvia de Sanjosé,Rolando Herrero,Xavier Castellsagué,Keerti V. Shah,Peter J.F. Snijders,Chris J.L.M. Meijer +7 more
TL;DR: In addition to HPV types 16 and 18, types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82Should be considered carcinogenic, or high-risk, types, and types 26, 53, and 66 should be considered probably carcinogenic.
Journal ArticleDOI
Equivalence of the Mediation, Confounding and Suppression Effect
TL;DR: The statistical similarities among mediation, confounding, and suppression are described and methods to determine the confidence intervals for confounding and suppression effects are proposed based on methods developed for mediated effects.
Journal ArticleDOI
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.
Stephanos J. Hadziyannis,Sette H,Timothy R. Morgan,Balan,Moisés Diago,Patrick Marcellin,G. Ramadori,Henry C. Bodenheimer,David I. Bernstein,Mario Rizzetto,Stefan Zeuzem,Paul J. Pockros,A. Lin,Andrew M. Ackrill +13 more
TL;DR: Treatment with peginterferon-alpha2a and ribavirin may be individualized by genotype, and in patients infected with HCV genotype 1, 48 weeks of treatment was statistically superior to 24 weeks and standard-dose ribvirin was statistically inferior to low-dose Ribavirin.